Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for DZD4205 (Golidocitinib) for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma
- Friday, February 18, 2022, 7:09
- Finance
- Add a comment
SHANGHAI, Feb. 18, 2022 /PRNewswire/ — Dizal Pharmaceutical Co., Ltd. (SHEX:688192) (“Dizal”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to DZD4205 (Golidocitinib) for the treatment of patients with Refractory or Relapsed…
About the Author
adminasapcorp has written 41802 stories on this site.